Lantheus Holdings sold 35,769 shares of Perspective Therapeutics at $3.12 per share on Sep. 1, 2026. The transaction matters because Lantheus remained invested in Perspective Therapeutics, owning 11,563,425 shares after the sale, while its stated status was a 10% owner.
Key Highlights
- The transaction took place on Sep. 1, 2026.
- Lantheus Holdings owned 11,563,425 Perspective Therapeutics shares after the sale.
- The transaction was recorded under sale code S.
Lantheus Holdings, Inc. (NASDAQ: LNTH) sold 35,769 shares of Perspective Therapeutics, Inc. at $3.12 per share. Lantheus Holdings is identified as a 10% owner of Perspective Therapeutics.
Perspective Therapeutics Shares Sold at $3.12
The transaction date was Sep. 1, 2026. The shares involved in the sale were shares of Perspective Therapeutics. The transaction was recorded under sale code S. The sale price was $3.12 per share. The reported transaction involved 35,769 shares, and the filing concerns Perspective Therapeutics shares rather than Lantheus Holdings’ own stock.
Post-Sale Perspective Therapeutics Position
Following the transaction, Lantheus Holdings owned 11,563,425 Perspective Therapeutics shares. The filing reports that Lantheus Holdings owned Perspective Therapeutics shares following the sale.
FAQs
Q: Why did Lantheus Holdings sell Perspective Therapeutics shares?
A: It reports a sale of 35,769 Perspective Therapeutics shares at $3.12 per share on Sep. 1, 2026, under sale code S.
Q: How many Perspective Therapeutics shares does Lantheus Holdings own?
A: Lantheus Holdings owned 11,563,425 Perspective Therapeutics shares after the transaction. The company is identified as a 10% owner of Perspective Therapeutics.
Q: What was the price of Lantheus Holdings’ Perspective Therapeutics stock sale?
A: The filing reports that Perspective Therapeutics shares were sold at $3.12 per share. Lantheus Holdings sold 35,769 shares in the transaction, which occurred on September 1, 2026.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.